J. Aycock

发表

Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma

R. Levy, J. Friedberg, I. Flinn, 2017, The New England journal of medicine.

Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

D. Miklos, C. Jacobson, N. Bartlett, 2017, Blood.

Use of saliva for assessment of stress and its effect on the immune system prior to gross anatomy practical examinations

J. Aycock, S. R. Lester, Roger B. Johnson, 2010, Anatomical sciences education.

Pharmacokinetics of Palifermin Administered as the Standard Dose and as a Collapsed Dose in Patients with Hematologic Malignancies

A. Cesano, J. Aycock, D. Hurd, 2007, Pharmacotherapy.

Effects of monoamine oxidase inhibitors on adrenal medullary responses to nicotine and tetramethylammonium.

J. Aycock, J. Gatgounis, 1963, The Journal of pharmacology and experimental therapeutics.

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

N. Bartlett, J. Rossi, S. Neelapu, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

AXICABTAGENE CILOLEUCEL (AXI‐CEL; KTE‐C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA‐1

D. Miklos, C. Jacobson, N. Bartlett, 2017 .

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

J. Friedberg, I. Flinn, D. Miklos, 2016 .

Influence of different levels of dietary pyridoxine on certain parameters of developing and mature brains in rats.

J. Aycock, A. Kirksey, 1976, The Journal of nutrition.

Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

D. Miklos, E. Jacobsen, N. Bartlett, 2017 .

Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).

D. Miklos, J. Rossi, C. Jacobson, 2017 .

A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1

A. LaCasce, C. Jacobson, N. Bartlett, 2016 .

Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

N. Bartlett, S. Neelapu, F. Locke, 2015 .

Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

M. Sabatino, J. Rossi, M. Bishop, 2017 .

Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

D. Miklos, C. Jacobson, J. Rossi, 2017 .

ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)

M. Kersten, G. Schiller, W. Wierda, 2016 .

Abstract CT019: Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL)

J. Friedberg, D. Miklos, J. Rossi, 2017 .

Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL): Long-Term Follow-up of the Pivotal Zuma-1 Trial

D. Miklos, J. Rossi, E. Jacobsen, 2018 .